Evidence map›Paper›PMID 34070414›Full record

ArticleMaterials (Basel, Switzerland)2021

Graphene Oxide Topical Administration: Skin Permeability Studies.

Filipa A L S Silva, Raquel Costa-Almeida, Licínia Timochenco, Sara I Amaral, Soraia Pinto, Inês C Gonçalves, José R Fernandes, Fernão D Magalhães, Bruno Sarmento, Artur M Pinto

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. New MoSPharmaceutics · 2024
    Article
  5. Review
  6. Article
  7. Toxicologic Concerns with Current Medical Nanoparticles.International journal of molecular sciences · 2022
    Review
  8. Graphene Oxide Thin Films with Drug Delivery Function.Nanomaterials (Basel, Switzerland) · 2022
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Filipa A L S Silvai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.
Raquel Costa-Almeidai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0001-7188-645X
Licínia TimochencoLEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculdade de Engenharia, Universidade do Porto, 4200-180 Porto, Portugal.
Sara I Amarali3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0003-3751-4673
Soraia Pintoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0003-3171-8122
Inês C Gonçalvesi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0001-9759-4965
José R FernandesCQVR-Centro de Química Vila Real, Universidade de Trás-os-Montes e Alto Douro, Quinta de Prados, 5001-801 Vila Real, Portugal.
Fernão D MagalhãesLEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculdade de Engenharia, Universidade do Porto, 4200-180 Porto, Portugal.ORCID 0000-0002-4447-4473
Bruno Sarmentoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0001-5763-7553
Artur M Pintoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-180 Porto, Portugal.ORCID 0000-0001-8184-8254

Funding

Base funding of the Laboratory for Process Engineering, Environment, Biotechnology and Energy UIDB/00511/2020European Regional Development Fund PO-CI-01-0145-FEDER-022122European Regional Development Fund POCI-01-0145-FEDER- 031143Fundação para a Ciência e a Tecnologia CEECIND/03908/2017Fundação para a Ciência e a Tecnologia SFRH/BD/144719/2019Fundação para a Ciência e a Tecnologia UID/BIM/04293/2019
6 · The paper itself

Abstract

Nanostructured carriers have been widely used in pharmaceutical formulations for dermatological treatment. They offer targeted drug delivery, sustained release, improved biostability, and low toxicity, usually presenting advantages over conventional formulations. Due to its large surface area, small size and photothermal properties, graphene oxide (GO) has the potential to be used for such applications. Nanographene oxide (GOn) presented average sizes of 197.6 ± 11.8 nm, and a surface charge of -39.4 ± 1.8 mV, being stable in water for over 6 months. 55.5% of the mass of GOn dispersion (at a concentration of 1000 µg mL

Indexed as

biocompatibilitycarbon nanomaterialsgraphitephototherapyskin disease

Identifiers

PMID34070414
PMCPMC8197561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.